PROSKit SIGNED

Project "PROSKit" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Arcis Biotechnology Holdings developed and patented PROSKit, a molecular diagnostic platform for the diagnosis of prostate cancer based on urine analysis, able to reduce the number of false positive from the PSA test and so the number of unnecessary biopsies. PROSKit is a proprietary mix of chemicals, that can stabilise nucleic acids (RNA/DNA) in urine for up to 2 weeks at room temperature and then allow sampling at home or Point of Care (PoC) using a patient-friendly sample collection technology, preserving unstable RNA biomarkers and analysis in specialized clinical environment through the PCA3 biomarker. With respect to current diagnostic methods (PSA biopsy), PROSKit offers i) Rapid- samples ready for analysis in <3 minutes, results in <2 hours if tested at surgery, compared to days for biopsy, ii) Accurate- greater sensitivity and specificity than current PSA blood test: PCA3 presents a 28% higher discriminative capability than PSA; iii) Inexpensive- as informative as multi-core biopsy for <10% of the price; iv) High throughput- PROSKit samples can be collected anywhere, non-invasively and thousands analysed simultaneously at a central location. Compared to competitors proposing RNA stabilization requiring laboratory analyses, complex procedures and specific tools, PROSKit offers stabilization at room temperature and with no lab equipment in 3 minutes. Intact amplifiable RNA biomarkers have already been validated for 7 days stability but needs to extend validation for >14 days, validate the protocol for patients to collect urine and analysts to perform assay; certify design of PROSKit device and cost for the device and define agreement with partners for distribution and license for execution of tests. DNA/RNA Sample preparation business market revenues are expected to reach 1.85 billion € in 2025. Kits segment represents 60% of the market: 1.11 billion € in 2025.